Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 3
1994 8
1995 2
1996 2
1997 1
1999 5
2000 6
2001 6
2002 4
2003 3
2004 6
2005 7
2006 3
2007 5
2008 5
2009 5
2010 4
2011 4
2012 1
2013 3
2014 5
2015 5
2016 3
2017 3
2018 2
2019 1
2020 3
2021 3
2022 4
2023 2
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.
Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Tabernero J, Li M, Ferrara S, Le Bruchec Y, Zhang G, Lu B, Biankin AV, Reni M; APACT Investigators. Tempero MA, et al. J Clin Oncol. 2023 Apr 10;41(11):2007-2019. doi: 10.1200/JCO.22.01134. Epub 2022 Dec 15. J Clin Oncol. 2023. PMID: 36521097 Free PMC article. Clinical Trial.
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, Görner M, Mölle M, Greten TF, Lakner V, Bischoff S, Sinn M, Dörken B, Pelzer U. Oettle H, et al. J Clin Oncol. 2014 Aug 10;32(23):2423-9. doi: 10.1200/JCO.2013.53.6995. Epub 2014 Jun 30. J Clin Oncol. 2014. PMID: 24982456 Clinical Trial.
Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression.
Cheung PF, Yang J, Fang R, Borgers A, Krengel K, Stoffel A, Althoff K, Yip CW, Siu EHL, Ng LWC, Lang KS, Cham LB, Engel DR, Soun C, Cima I, Scheffler B, Striefler JK, Sinn M, Bahra M, Pelzer U, Oettle H, Markus P, Smeets EMM, Aarntzen EHJG, Savvatakis K, Liffers ST, Lueong SS, Neander C, Bazarna A, Zhang X, Paschen A, Crawford HC, Chan AWH, Cheung ST, Siveke JT. Cheung PF, et al. Among authors: oettle h. Nat Commun. 2022 Jan 10;13(1):156. doi: 10.1038/s41467-021-27088-9. Nat Commun. 2022. PMID: 35013174 Free PMC article.
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116).
Modest DP, Heinemann V, Schütt P, Angermeier S, Haberkorn M, Waidmann O, Graeven U, Wille K, Kunzmann V, Henze L, Constantin C, de Wit M, Denzlinger C, Ballhausen A, Kurreck A, Jelas I, Alig AHS, Stahler A, Stintzing S, Oettle H. Modest DP, et al. Among authors: oettle h. J Cancer Res Clin Oncol. 2024 Jul 1;150(7):332. doi: 10.1007/s00432-024-05827-x. J Cancer Res Clin Oncol. 2024. PMID: 38951245 Free PMC article. Clinical Trial.
Transforming growth factor beta in pancreatic cancer.
Hilbig A, Oettle H. Hilbig A, et al. Among authors: oettle h. Curr Pharm Biotechnol. 2011 Dec;12(12):2158-64. doi: 10.2174/138920111798808356. Curr Pharm Biotechnol. 2011. PMID: 21619533 Review.
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial.
Dorman K, Boeck S, Caca K, Reichert M, Ettrich TJ, Oettle H, Waidmann O, Modest DP, Müller L, Michl P, Kanzler S, Pink D, Reinacher-Schick A, Geißler M, Pelz H, Kunzmann V, Held S, Schichtl T, Heinemann V, Kullmann F. Dorman K, et al. Among authors: oettle h. Lancet Gastroenterol Hepatol. 2024 Oct;9(10):935-943. doi: 10.1016/S2468-1253(24)00197-3. Epub 2024 Aug 16. Lancet Gastroenterol Hepatol. 2024. PMID: 39159648 Clinical Trial.
[S3-guideline exocrine pancreatic cancer].
Seufferlein T, Porzner M, Becker T, Budach V, Ceyhan G, Esposito I, Fietkau R, Follmann M, Friess H, Galle P, Geissler M, Glanemann M, Gress T, Heinemann V, Hohenberger W, Hopt U, Izbicki J, Klar E, Kleeff J, Kopp I, Kullmann F, Langer T, Langrehr J, Lerch M, Löhr M, Lüttges J, Lutz M, Mayerle J, Michl P, Möller P, Molls M, Münter M, Nothacker M, Oettle H, Post S, Reinacher-Schick A, Röcken C, Roeb E, Saeger H, Schmid R, Schmiegel W, Schoenberg M, Siveke J, Stuschke M, Tannapfel A, Uhl W, Unverzagt S, van Oorschot B, Vashist Y, Werner J, Yekebas E; Guidelines Programme Oncology AWMF; German Cancer Society eV; German Cancer Aid. Seufferlein T, et al. Among authors: oettle h. Z Gastroenterol. 2013 Dec;51(12):1395-440. doi: 10.1055/s-0033-1356220. Epub 2013 Dec 11. Z Gastroenterol. 2013. PMID: 24338757 Free article. German. No abstract available.
114 results